Dividend Adjusted Return
Nov 13, 2025 - Nov 13, 2026MRK 147.76 (+66.3%)
Healthcare 347.93 (+24.3%)
S&P 500 7561.67 (+11.6%)






Stock Rover estimates Merck & Co’s intrinsic (fair) value at $149.00, against a recent price of $147.76, a margin of safety of 1%. Quantitative scores (0–100): Value 61, Quality 64, Growth 77, Sentiment 91. Analyst consensus: Buy.







Fair Value | $149.00 | |
Margin of Safety | 1% |
Value Score 61 Value Score: Our value score looks at EV/EBITDA, P/E, P/S, P/TB (Price/Tangible Book) and EPS Predictability. P/S and P/TB are compared within a sector. Other metrics are compared across all stocks | Quality Score 64 Quality Score: Our quality score compares profitability and balance sheet metrics to find high quality companies using ROIC, Net Margin, Gross Margin, Interest Coverage, and Debt / Equity metrics. |
Growth Score 77 Growth Score: Our growth score looks at the 5 year history and the forward estimates for EBITDA, Sales, and EPS growth, ranking the best companies across all stocks. | Sentiment Score 91 Sentiment Score: Our sentiment score finds stocks in favor by analyzing Short Interest, returns in key periods over the last year, Price vs. 52-wk High, Days Since 52-wk High and MACD signals. |
| MRK | Industry | S&P 500 | |
|---|---|---|---|
| Value Score | 61 | 69 | 68 |
| Price / Earnings | 149.3 | 34.7 | 24.9 |
| Price / Sales | 5.4 | 5.3 | 3.5 |
| Price / Free Cash Flow | 24.8 | 28.8 | 35.4 |
| Price / Book | 8.1 | 7.5 | 5.6 |
| Price / Tangible Book | - | - | 361.3 |
| EV / EBITDA | 29.1 | 23.6 | 18.1 |
| EPS Predict. Pctl. | 52 | 72 | 71 |
| Piotroski F Score | 5 | 6 | 7 |
| 5‑Year P/E Range | 10.9 500+ |
| 5‑Year P/B Range | 4.0 9.0 |
| 5‑Year P/S Range | 2.9 5.9 |
| MRK | Industry | S&P 500 | |
|---|---|---|---|
| Growth Score | 77 | 69 | 79 |
| Sales Growth | |||
| Sales Growth Next Year | 3.3% | 16.7% | 20.6% |
| Sales 1‑Year Chg (%) | 4.9% | 17.5% | 19.3% |
| Sales 3‑Year Avg (%) | 4.3% | 17.0% | 14.8% |
| Sales 5‑Year Avg (%) | 7.9% | 9.4% | 13.3% |
| EPS Growth | |||
| Next Yr. Growth Est. | 223.1% | 35.1% | 15.4% |
| EPS 1‑Year Chg (%) | -86.9% | 26.4% | 44.9% |
| EPS 3‑Year Avg (%) | -18.3% | 37.9% | 20.4% |
| EPS 5‑Year Avg (%) | -15.7% | 23.2% | 15.4% |






JNJ | Johnson & Johnson | $687,888 | 43.4 | 1.9% | 14.9% | 49.6% | -4% | 63 | 79 | 95 |
ABBV | AbbVie | $521,499 | 50.7 | 2.4% | 8.2% | 30.8% | 1% | 57 | 91 | 87 |
MRK | Merck & Co | $364,264 | 149.3 | 2.3% | 4.1% | 63.7% | 1% | 61 | 77 | 64 |
NVS | Novartis | $303,124 | 30.6 | 3.0% | 12.7% | 25.4% | 2% | 72 | 80 | 91 |
AZN | AstraZeneca | $286,066 | 26.1 | 1.7% | 18.4% | 5.7% | -2% | 64 | 94 | 94 |
AMGN | Amgen | $251,886 | 27.0 | 2.2% | 12.8% | 42.4% | -10% | 69 | 90 | 89 |
GILD | Gilead Sciences | $208,476 | - | 2.0% | 13.6% | 37.6% | -21% | 61 | 60 | 77 |
NVO | Novo Nordisk | $183,519 | 10.5 | 4.3% | 9.4% | -11.2% | -5% | 85 | 77 | 83 |
PFE | Pfizer | $164,668 | 41.3 | 6.0% | 1.8% | 17.8% | 27% | 72 | 44 | 83 |
BMY | Bristol-Myers Squibb | $129,656 | 14.1 | 4.0% | 11.9% | 36.2% | 27% | 79 | 56 | 91 |
SNY | Sanofi | $116,134 | 24.1 | 5.0% | 23.6% | -2.5% | 16% | 87 | 81 | 89 |
GSK | GSK | $101,125 | 17.6 | 3.6% | 9.0% | 8.5% | 30% | 82 | 81 | 90 |
| MRK | Industry | S&P 500 | |
|---|---|---|---|
| Quality Score | 64 | 79 | 77 |
| Gross Margin | 71.8% | 73.2% | 33.2% |
| Operating Margin | 9.2% | 27.8% | 17.4% |
| Net Margin | 3.6% | 15.2% | 14.2% |
| Return on Assets | 1.9% | 10.5% | 14.1% |
| Return on Equity | 5.5% | 34.8% | 37.7% |
| ROIC | 3.2% | 22.4% | 24.1% |
| MRK | Industry | S&P 500 | |
|---|---|---|---|
| Sentiment Score | 91 | 65 | 71 |
| 5‑Day Return | 0.7% | 2.6% | 2.5% |
| 1‑Month Return | 4.1% | 13.7% | -3.1% |
| YTD Return | 43.3% | 26.1% | 11.3% |
| 1‑Year Return | 63.7% | 32.2% | 13.4% |
| 3‑Year Return | 58.0% | 73.8% | 77.8% |
| 5‑Year Return | 105.0% | 84.6% | 72.7% |
| Beta 1‑Year | 0.22 | 0.19 | 1.00 |






| MRK | Industry | |
|---|---|---|
| Forward Dividend Yield | 2.3% | 2.0% |
| Payout Ratio | 340.0% | 42.7% |
| TTM Yield | 2.3% | - |
| Fwd. Div. Per Share | $3.40 | $4.54 |
| Div. 1Y Chg (%) | 4.9% | - |
| Div. 3Y Avg (%) | 5.2% | - |
| Div. 5Y Avg (%) | 5.5% | - |
| Cons. Growth Years | 10+ | - |
| Div. Coverage Ratio | 0.3 | 1.4 |
| Current Ratio | 1.4 |
| Quick Ratio | 1.1 |
| Price | $147.76 |
| Net Cash Per Share | -$17.84 |
| Equity Per Share | $18.20 |
| Debt / Equity | 1.2 |
| Solvency Ratio | 12% |
| Interest Coverage | 3.4 |
| Short % of Float | 1.1% |
| Altman Z‑Score | 3.9 |
| Current Quarter EPS | |
|---|---|
# Up Last 30 days | 1.00 |
# Down Last 30 days | 12.00 |
Mean Estimate | 1.76 |
% Change (30 Days) | -9.91% |
| Next Quarter EPS | |
|---|---|
# Up Last 30 days | 2.00 |
# Down Last 30 days | 4.00 |
Mean Estimate | 2.13 |
% Change (30 Days) | -1.44% |
| Cur Qtr | Next Qtr | Cur Year | Next Year | |
|---|---|---|---|---|
| Latest | $1.76 | $2.13 | $2.78 | $8.98 |
| 30 Days Ago | $1.95 | $2.16 | $2.69 | $9.32 |
| 90 Days Ago | $1.95 | $2.21 | $2.74 | $9.55 |
| % Change (90 Days) | -10.0% | -3.5% | 1.4% | -5.9% |
| Surprise Type | Amount | Percent |
|---|---|---|
| Positive Quarters (> 2%) | 10 | 83.3% |
| Negative Quarters (< 2%) | 0 | - |
| In-Line Quarters (within 2%) | 2 | 16.7% |
| Surprise Type | Announce Date | Period End Date | Actual EPS | Est. EPS | Surprise (%) |
|---|---|---|---|---|---|
| Positive | 10/29/26 | 09/30/26 | $2.49 | $2.12 | 17.5% |
| Positive | 08/04/26 | 06/30/26 | -$0.13 | -$0.26 | 50.0% |
| Positive | 04/30/26 | 03/31/26 | -$1.28 | -$1.51 | 15.2% |
| In-Line | 02/03/26 | 12/31/25 | $2.04 | $2.03 | 0.5% |
| Positive | 10/30/25 | 09/30/25 | $2.58 | $2.36 | 9.3% |
| Positive | 07/29/25 | 06/30/25 | $2.13 | $2.01 | 6.0% |
| MRK | Industry | S&P 500 | |
|---|---|---|---|
| Best Monthly Return (5Y) | 27.1% | 13.1% | 9.6% |
| Worst Monthly Return (5Y) | -14.7% | -6.8% | -9.6% |
| Beta 1‑Year | 0.22 | 0.19 | 1.00 |
| Volatility 1‑Year | 0.29 | 0.17 | 0.13 |
| Volatility 1Y Pctl. | 28 | - | - |
| Max Drawdown 1‑Year | -11.4% | -19.7% | -8.8% |
| Max Drawdown 3‑Year | -43.4% | -27.6% | -18.7% |
| Max Drawdown 5‑Year | -43.4% | -30.4% | -24.6% |











AZN | AstraZeneca | 90 | 6.7% | 23.5% | 6.3% | 7.3% | 11.5% | 13.7% |
ABBV | AbbVie | 87 | 10.3% | 2270.0% | 9.1% | 10.7% | 6.2% | 3.7% |
AMGN | Amgen | 80 | 8.5% | 19.4% | 4.6% | 8.2% | 13.2% | 8.6% |
NVS | Novartis | 30 | 4.7% | -68.8% | 6.9% | 1.8% | 7.7% | 1.8% |
MRK | Merck & Co | 22 | 4.7% | -12.1% | 3.3% | 4.9% | 4.3% | 7.9% |
AZN | AstraZeneca | 73 | 26.1 | 16.3 | 0.6 | 4.6 | 5.5 | 22.0 - |
AMGN | Amgen | 39 | 27.0 | 18.6 | 2.2 | 6.5 | 17.6 | 14.9 56.4 |
ABBV | AbbVie | 33 | 50.7 | 18.2 | 7.5 | 7.9 | - | 19.0 178.9 |
NVS | Novartis | 18 | 30.6 | 16.1 | 7.9 | 5.4 | 8.1 | 7.0 33.1 |
MRK | Merck & Co | 2 | 149.3 | 16.5 | - | 5.4 | 8.1 | 10.9 500+ |
NVS | Novartis | 100 | 74.9% | 25.2% | 17.5% | 11.7% 40.6% | 4.9% 18.5% |
MRK | Merck & Co | 85 | 71.8% | 9.2% | 3.6% | 1.0% 38.3% | 0.4% 16.5% |
AZN | AstraZeneca | 83 | 81.9% | 23.5% | 17.7% | -3.5% 21.9% | -1.3% 9.5% |
AMGN | Amgen | 80 | 70.9% | 32.4% | 24.1% | 52.8% 624.8% | 3.4% 11.8% |
ABBV | AbbVie | 72 | 73.7% | 36.0% | 15.7% | -100.0% 294.7% | 1.7% 9.3% |
AZN | AstraZeneca | 77 | 0.7 | 8.4 | 0.8 | 49.5% | 29% | 0.2% |
MRK | Merck & Co | 75 | 1.2 | 3.4 | 1.1 | 35.0% | 12% | 1.1% |
NVS | Novartis | 69 | 1.3 | 9.0 | 0.6 | 57.2% | 25% | 0.2% |
ABBV | AbbVie | 55 | - | 5.3 | 0.8 | 64.0% | 16% | 1.0% |
AMGN | Amgen | 49 | 3.8 | 5.2 | 1.2 | 39.8% | 19% | 2.3% |
NVS | Novartis | 89 | 3.0% | 3.0% | $160.50 | $4.74 | 10+ | 90.0% |
AMGN | Amgen | 55 | 2.2% | 2.1% | $465.67 | $10.08 | 10+ | 57.2% |
MRK | Merck & Co | 55 | 2.3% | 2.3% | $147.76 | $3.40 | 10+ | 340.0% |
ABBV | AbbVie | 46 | 2.4% | 2.4% | $295.03 | $6.92 | 10+ | 117.4% |
AZN | AstraZeneca | 41 | 1.7% | 1.7% | $184.45 | $3.20 | 5 | 45.0% |
AMGN | Amgen | 98 | 12.8% | 12.1% | 40.3% | 45.2% | 42.4% | 0.49 | 0.28 | 96.2% |
ABBV | AbbVie | 97 | 8.2% | 18.3% | 43.4% | 33.0% | 30.8% | -0.02 | 0.25 | 97.4% |
MRK | Merck & Co | 96 | 4.1% | 9.7% | 32.0% | 43.3% | 63.7% | 0.22 | 0.29 | 94.2% |
NVS | Novartis | 92 | 12.7% | 5.8% | 7.2% | 19.9% | 25.4% | 0.36 | 0.27 | 94.2% |
AZN | AstraZeneca | 86 | 18.4% | 17.3% | -1.1% | 6.9% | 5.7% | 0.17 | 0.30 | 86.7% |





2026 Dividends | $2.55 |
09/15/26 | 10/07/26 | Regular | $0.85 |
06/15/26 | 07/08/26 | Regular | $0.85 |
03/16/26 | 04/07/26 | Regular | $0.85 |
2025 Dividends | $3.28 |
12/15/25 | 01/08/26 | Regular | $0.85 |
09/15/25 | 10/07/25 | Regular | $0.81 |
06/16/25 | 07/08/25 | Regular | $0.81 |
03/17/25 | 04/07/25 | Regular | $0.81 |
2024 Dividends | $3.12 |
12/16/24 | 01/08/25 | Regular | $0.81 |
09/16/24 | 10/07/24 | Regular | $0.77 |
06/17/24 | 07/08/24 | Regular | $0.77 |
03/14/24 | 04/05/24 | Regular | $0.77 |
2023 Dividends | $2.96 |
12/14/23 | 01/08/24 | Regular | $0.77 |
09/14/23 | 10/06/23 | Regular | $0.73 |
06/14/23 | 07/10/23 | Regular | $0.73 |
03/14/23 | 04/10/23 | Regular | $0.73 |
2022 Dividends | $2.80 |
12/14/22 | 01/09/23 | Regular | $0.73 |
09/14/22 | 10/07/22 | Regular | $0.69 |
06/14/22 | 07/08/22 | Regular | $0.69 |
03/14/22 | 04/07/22 | Regular | $0.69 |
Ex-Dividend Date | 09/15/26 |
Payment Date | 10/07/26 |
Amount | $0.85 |
Type | Regular |
Regular Dividend | $0.85 |
Forward Dividend Rate | $3.40 |
Forward Dividend Yield | 2.3% |
Trailing 12 Months Dividends | $3.40 |
Trailing 12 Months Yield | 2.3% |
Payout Ratio | 340.0 |
Dividend Coverage Ratio | 0.3 |
Consecutive Growth Years | 10+ |
3 Year Growth Rate | 5.2% |
5 Year Growth Rate | 5.5% |
10 Year Growth Rate | 6.3% |
Price / Earnings | 149.3 | 14.3 | 18.2 | 84.0 | 14.9 |
Price / Cash Flow | 19.6 | 13.7 | 13.7 | 15.2 | 12.6 |
Price / Book | 8.1 | 4.8 | 5.7 | 6.7 | 5.7 |
Price / Tangible Book | - | 15.5 | 43.0 | 300.7 | 128.6 |
Price / Sales | 5.4 | 3.7 | 4.0 | 4.5 | 4.4 |
EV / EBITDA | 29.1 | 9.3 | 14.3 | 23.6 | 12.5 |
Forward Dividend Yield | 2.3% | 3.5% | 3.1% | 2.9% | 2.8% |
Shareholder Yield | 3.3% | 5.4% | 3.6% | 3.2% | 2.8% |
Gross Margin | 71.8% | 77.2% | 75.8% | 72.9% | 70.5% |
Net Margin | 3.6% | 29.6% | 19.2% | 7.8% | 25.9% |
Return on Assets | 1.9% | 16.0% | 11.1% | 4.3% | 14.7% |
Return on Equity | 5.5% | 36.7% | 27.3% | 11.2% | 34.3% |
ROIC | 3.2% | 21.0% | 15.2% | 6.6% | 22.5% |
Additional data provided by Zacks, Intrinio, Quandl, Yodlee, IEX Cloud
MRK has outperformed its sector by 42.1% in the past year.
The Healthcare sector has outperformed the market by 12.7% in the past year.